Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation: a Clinical Study

NCT05460195 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT05460195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05460195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation: a Clinical Study
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2022
Completion date
December 31, 2024
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-angiogenesis, immunotherapy, minimal residual disease, non-small cell lung cancer